Sugi Predict

Sugi Predict / Compounds / SCHEMBL12468872

SCHEMBL12468872

SCHEMBL12468872

CC(C)(C)OC(=O)c1cccc(Cl)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.43
▸ ALDH1A1 P00352 4/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ HPGDS O60760 1/20 0.40
▸ GABRP O00591 1/20 0.40
▸ GABRD O14764 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRB1 P18505 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA5 P31644 1/20 0.40
▸ GABRA3 P34903 1/20 0.40
▸ GABRA2 P47869 1/20 0.40
▸ GABRB2 P47870 1/20 0.40
▸ GABRA4 P48169 1/20 0.40
▸ GABRE P78334 1/20 0.40
▸ GABRA6 Q16445 1/20 0.40
▸ GABRG1 Q8N1C3 1/20 0.40
▸ GABRG3 Q99928 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30077004 1.00 CYP1A2 (0.43) CYP1A2ALDH1A1CYP3A4TSHRHPGDS
SCHEMBL32315381 0.81 P2RX7 (0.50) CYP1A2ALDH1A1CYP3A4HPGDSGABRP
SCHEMBL946380 0.81 P2RX7 (0.50) CYP1A2ALDH1A1CYP3A4HPGDSGABRP
SCHEMBL31264274 0.80 CYP1A2 (0.55) CYP1A2ALDH1A1CYP3A4TSHRL3MBTL1
SCHEMBL400889 0.80 CYP1A2 (0.55) CYP1A2ALDH1A1CYP3A4TSHRL3MBTL1
SCHEMBL31746517 0.79 GRM5 (0.44) CYP1A2ALDH1A1TSHRHPGDSGABRP
SCHEMBL29498377 0.79 CYP1A2 (0.43) CYP1A2ALDH1A1TSHRHPGDSGABRP
SCHEMBL594691 0.79 GRM5 (0.44) CYP1A2ALDH1A1TSHRHPGDSGABRP
SCHEMBL13755312 0.79 CYP1A2 (0.43) CYP1A2ALDH1A1CYP3A4TSHRHPGDS
SCHEMBL2478010 0.79 CYP1A2 (0.43) CYP1A2ALDH1A1TSHRHPGDSGABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388593-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2025-12-25 — — US disclosed
EP-4650348-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR Mitsubishi Tanabe Pharma Corporation (JP) 2025-11-19 — — EP disclosed
WO-2024150815-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR 田辺三菱製薬株式会社 2024-07-18 — — WO disclosed
EP-3455224-B1 SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF BAYER AG (DE) 2024-03-27 — — EP disclosed
US-20220348577-A1 CXCR4 Receptor Antagonists PROXIMAGEN LLC (US) 2022-11-03 — — US disclosed
CN-109476658-B Substituted 5,6,7, 8-tetrahydro [1,2,4] triazolo [4,3-a ] pyridin-3 (2H) -ones and 2,5,6, 7-tetrahydro-3H-pyrrolo [2,1-c ] [1,2,4] triazol-3-ones and uses thereof 拜耳公司 2021-08-10 — — CN disclosed
US-10995091-B2 CXCR4 receptor antagonists PROXIMAGEN LLC (US) 2021-05-04 — — US disclosed
US-10995091-B2 CXCR4 receptor antagonists PROXIMAGEN LLC (US) 2021-05-04 — — US disclosed
EP-3484879-B1 HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY CHIESI FARM SPA (IT) 2020-12-30 — — EP disclosed
WO-2020222190-A1 CRYSTALLINE FORM OF 6-[4-[1 -(PROPAN-2-YL)PIPERIDIN-4-YL]-1,4-DIAZEPAN-1 -YL]-N-(PYRDIN-4-YL)PYRIDINE-2-CARBOXAMIDE PROXIMAGEN, LLC (US) 2020-11-05 — — WO disclosed
US-20160046606-A1 CXCR4 Receptor Antagonists PROXIMAGEN LIMITED (GB) 2016-02-18 — — US disclosed
EP-2927224-A1 Receptor antagonists Proximagen Limited (GB) 2015-10-07 — — EP disclosed
EP-2627649-B1 CXCR4 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2015-04-08 — — EP disclosed
EP-2627649-B1 CXCR4 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2015-04-08 — — EP disclosed
US-20130289020-A1 CXCR4 Receptor Antagonists PROXIMAGEN LIMITED (GB) 2013-10-31 — — US disclosed
US-20130289020-A1 CXCR4 Receptor Antagonists PROXIMAGEN LIMITED (GB) 2013-10-31 — — US disclosed
CN-103282360-A Cxcr4 receptor antagonists PROXIMAGEN LTD 2013-09-04 — — CN disclosed
EP-2627649-A1 CXCR4 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-21 — — EP disclosed
WO-2012049277-A1 CXCR4 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-19 — — WO disclosed
WO-2012049277-A1 CXCR4 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348577-A1 CXCR4 Receptor Antagonists CXCR4, CXCR1, CXCR2 CYP1A2 1917/4885ALDH1A1 886/4885CYP3A4 2439/4885
US-20130289020-A1 CXCR4 Receptor Antagonists CXCR4, ACKR3, CXCR1 CYP1A2 4638/4885ALDH1A1 1948/4885CYP3A4 4130/4885
US-20160046606-A1 CXCR4 Receptor Antagonists CXCR4, CXCR1, CXCR2 CYP1A2 1917/4885ALDH1A1 886/4885CYP3A4 2439/4885
US-20250388593-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR CRBN, CUL1, CBL CYP1A2 1719/4885ALDH1A1 579/4885CYP3A4 1423/4885
US-10995091-B2 CXCR4 receptor antagonists CXCR4, CXCR1, CXCR2 CYP1A2 1917/4885ALDH1A1 886/4885CYP3A4 2439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.